Overcoming barriers to hepatitis C treatment among substance users


Marija Zeremski, PhD,

Project Director, Clinical Directors Network (CDN)

A live webcast sponsored by:

Merck (Grant No. AAN170209041806), The N2 PBRN Virtual Training Series (AHRQ, Grant No. 1P30-HS-021667) and Clinical Directors Network, Inc. (CDN)

Summary of Session Goals:

Substance users have the highest prevalence of hepatitis C virus (HCV) infection but are very rarely treated. Despite recent approval of HCV treatment regimens with almost universal efficacy, complete eradication of HCV will not be possible before all patient populations have access to treatment. In this webcast we will:


Monday, October 2, 2017 from 1:00 PM to 2:30 PM EDT


Overcoming Barriers to Hepatitis C Treatment Among Substance Users (PDF)

Continuing Education Evaluations:

This activity has been reviewed and approved for up to 1.5 Prescribed credit(s) by the American Academy of Family Physicians (AAFP).

Recent Webcasts

Sex in the Time of COVID-19

Kenneth H. Mayer, M.D., Medical Research Director, Fenway Health, Co-Director, The Fenway Institute, Professor of Medicine, Harvard Medical School, Attending Physician, Infectious Disease...

Opioid Prescribing in the COVID-19 Era

Joanna L. Starrels, MD, MS, FACP, Associate Professor of Medicine, Albert Einstein College of Medicine and Montefiore Medical Center, Division of General Internal Medicine
Hector R. Perez,...

Prescription Pain Medication Use in the Community

Linda B. Cottler, PhD, MPH, FACE, Associate Dean for Research, College of Public Health and Health Professions and Dean's Professor of Epidemiology at the University of Florida